Celltrion Files Marketing Authorization Application in Korea for Cosentyx Biosimilar CT-P55 Based on Positive Phase 1 Results
Celltrion has submitted a marketing authorization application to the Korea Ministry of Food and Drug Safety for CT-P55, a biosimilar of Cosentyx indicated for psoriasis and psoriatic arthritis.
The application is based on positive Phase 1 results from 172 healthy adults demonstrating pharmacokinetic equivalence, comparable safety, and similar immunogenicity to the reference product.
Celltrion plans to pursue additional regulatory approvals across global markets, which is expected to strengthen its biosimilar portfolio and drive long-term revenue growth.
However, approval is not guaranteed and depends on the regulator's final review; investors should weigh this uncertainty as a key risk factor.
[AI Summary]Celltrion's filing for CT-P55 in Korea is a neutral event with no immediate impact on capital structure or shareholder value. While the Phase 1 success is a positive development, the final approval timeline and market entry remain uncertain, with potential long-term strategic benefits from biosimilar market expansion.
KOSPI Filing Information
Report on Major Management Matters Related to Investment Decision (CTP55 (Cosentix Biosimilar) Application for Korean Product Approval)